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ABSTRACT 
LAUREN GRACE DAIGLE: Evaluation of the Prevalence and Treatment Trends of 
Diabetic Peripheral Neuropathy among Patients with Diabetes in a Rural Population 
(Under the direction of Dr. Matthew W. Strum) 
 
Evidence for adherence to the American Diabetes Association’s (ADA) screening 
and treatment guidelines for various health complications of diabetes in rural populations 
is limited. The ADA recommends annual foot and eye exams and supports the use of the 
Semmes-Weinstein monofilament (SWM) to detect signs of diabetic peripheral 
neuropathy (DPN). This study evaluated the prevalence and treatment trends of DPN 
among patients with diabetes in a rural population. Fifty-two individuals over the age of 
18, with known Type 1 or Type 2 diabetes mellitus, were recruited to participate. 
Participants were asked to respond to a 29-item, multiple choice and freeform question 
survey about the monitoring and management of their diabetes. A monofilament exam 
was then performed on each participant using a 10g SWM to detect signs of DPN. Six 
locations on the foot were tested with the 10g SWM, and a pedal pulse was recorded. The 
results of the 10g SWM exam were compared to the survey responses for each 
corresponding participant. Survey responses indicated that 21.2% of participants had 
been diagnosed with DPN. Although not statistically significant due to limited sample 
size, 17.3% of participants were identified by the SWM exam to have DPN but were 
currently undiagnosed by their physician. Furthermore, 12.0% of participants had not had 
an eye exam in over a year, and 28.8% did not have regular foot exams. Participants 
	 vi	
whose physicians performed regular foot exams were 3.0 times as likely to have an eye 
exam within the last year compared to participants whose physicians did not perform 
regular foot exams, demonstrating a positive correlation between foot and eye exams. 
The health consequences of undiagnosed sequelae of diabetes can be devastating. More 
specific data related to diabetes management and prevention of disease complications 
(via appropriate screening processes) in underserved areas is warranted; however, this 
study suggests that rural populations need greater attention and targeted educational 
programs to enhance the level of care.  
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INTRODUCTION 
Diabetes mellitus is defined as “a group of diseases that affect how your body 
uses blood sugar”.1 Diabetes mellitus is traditionally divided into two different subtypes, 
type 1 (T1DM) and type 2 (T2DM). T1DM, previously referred to as insulin-dependent 
diabetes mellitus, is more commonly diagnosed in children and results from defected β 
cells in the pancreas, preventing the body from making insulin.2,3 T2DM, or non-insulin 
dependent diabetes mellitus, differs from T1DM in that it develops when the body 
becomes resistant to insulin, and eventually, the production of insulin becomes 
inadequate. T2DM accounts for 90-95% of all diagnosed cases of diabetes.4,5   
Insulin is a hormone that is secreted into the bloodstream by the β cells in the 
pancreas. Responsible for the uptake of glucose from the blood into cells, insulin lowers 
the blood glucose concentration. However, in diabetes, blood glucose levels rise as a 
result of either the lack of insulin (T1DM) or the body’s unresponsiveness to insulin, 
known as insulin resistance (T2DM). In order for insulin to function, it must attach to, 
and then stimulate, specific receptors on the surface of cells.6 This process allows insulin 
receptor substrate to be moved to the plasma membrane. Glucose is subsequently 
transported into the cell where activation of several intracellular metabolic processes 
occurs.6  
In T2DM, the ability to stimulate the insulin receptor substrate is impaired.6  As a 
result, blood glucose levels rise, causing the β cells to produce more insulin in an attempt 
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to increase the uptake of glucose into cells. High demand on the β cells to hypersecrete 
insulin leads to β cell dysfunction and ultimately β cell death.6  In contrast, T1DM results 
from an abnormal immune response against the pancreatic β cells or from defected β 
cells causing little or no insulin to be produced. Consequently, the insulin necessary to 
participate in the pathway of glucose uptake into cells is unavailable. As a result, both 
T1DM and T2DM cause glucose to accumulate in the blood, often having damaging 
effects on the body.3,6  
The risk factors for T1DM include having a family history of T1DM, geography, 
and age. Individuals with a parent or sibling with T1DM are at an increased risk of 
developing the condition because they are more likely to possess specific genes 
associated with diabetes. An increased distance from the equator puts individuals at a 
higher risk for developing T1DM as well due to less exposure to ultraviolet light and 
lower vitamin D levels.7 T1DM is most common between the ages of four and seven and 
again between ten and fourteen years of age.8  
On the other hand, the risk factors for T2DM are quite different. Risk factors 
include body weight, abdominal fat distribution, physical inactivity, family history, race, 
age, prediabetes, polycystic ovary syndrome, and gestational diabetes.3 The primary risk 
factor for developing T2DM is being overweight.3 High levels of fatty tissue cause cells 
to become more resistant to insulin, consequently increasing blood glucose levels.3 Fat 
storage distribution also influences risks for T2DM as storing fat primarily in the 
abdomen puts individuals at a greater risk than storing fat in the hips and thighs.3 
Additionally, lack of physical activity increases the risk of T2DM. Physical activity uses 
glucose for energy and makes cells more sensitive to the presence of insulin.3 Lack of 
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physical activity consequently decreases the body’s sensitivity to insulin and can cause 
the elevated blood glucose levels indicative of diabetes. A family history of T2DM as 
well as being male, African American, American Indian, or Asian-American puts 
individuals at a higher risk for developing the condition due to the presence of certain 
genetic factors.3 Unlike T1DM, the risk for developing T2DM increases with age, 
especially after age 45.3 Another risk factor, prediabetes, is when the blood glucose levels 
are abnormally high, but not high enough to be considered diabetes.3 Prediabetes is often 
a sign that the body is progressing towards a diabetic state.3 Lastly, polycystic ovary 
syndrome as well as gestational diabetes in women has been correlated with an increased 
risk for developing diabetes.3   
Diabetes is typically diagnosed through blood tests (See Figure 1).9,10 The normal 
glucose levels for a non-diabetic are 80-120 mg/dL before meals, 160 mg/dL or less two 
hours after meals, and 100 mg/dL to 140 mg/dL at bedtime.11  Each test has slightly 
different criteria that must be met. An A1C test is a way to measure blood glucose levels 
for the past 2 to 3 months without the need for the individual to fast.12 The Fasting 
Plasma Glucose test checks fasting blood glucose levels after an individual has not 
consumed food or drink for 8 hours prior to the test.12 The Oral Glucose Tolerance Test 
checks blood glucose levels before and 2 hours after consumption of a sweet drink.12 
Finally, the Random Plasma Glucose Test is a test done on the blood at any time of day 
when diabetes symptoms are severe.12 Use of such blood tests can provide the 
information necessary for a proper diagnosis of diabetes.  
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FIGURE 1: Criteria for the Diagnosis of Diabetes. From Standards of Medical Care in 
Diabetes—2016 
 
 
Some common symptoms of diabetes include excessive thirst and hunger, fatigue, 
blurry vision, slow healing bruises, weight loss, and pain or numbness in the hands and 
feet.13 As the condition progresses, other organs may be affected and other symptoms 
may occur.13  
Diabetes is the seventh leading cause of death in the United States today. 5 
Roughly 29.1 million Americans had diabetes in 2014, with 1.7 million new diagnoses. 
5,14  There are 21.0 million diagnosed cases of diabetes and 8.1 million undiagnosed 
cases. Diabetes affects various ethnicities differently.5 Diabetes is most prominent among 
American Indians/Alaska Natives, non-Hispanic blacks, Asian Americans and Hispanics. 
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Roughly 16% of the American Indians/Alaska Natives population has diagnosed 
diabetes, making it the ethnicity with the highest percentage of diagnosed diabetes.5 The 
differences in genetic factors as well as lifestyles impact the prevalence of diabetes 
among various ethnicities.5  More importantly, 86 million adult Americans have 
prediabetes, and as many as 1 in 3 Americans are expected to have diabetes in 2050 if 
trends continue.5,14  
On a more local level, approximately 11.7% of adult Mississippians had a 
diagnosis of diabetes in 2012.5 The Mississippi State Department of Health reported that, 
in 2012, Mississippi ranked first in the nation for cases of diagnosed diabetes while 
Louisiana ranked second.5,15 Statistics show that 11.5% of the adult population in 
Louisiana had a diagnosis of diabetes in 2012.5 Diabetes is clearly a condition that holds 
great prevalence throughout the U.S. and particularly in the Southeast.  A significant 
portion of the United States’ population is affected by diabetes, costing over $245 billion 
per year in healthcare.5 In Mississippi, the estimated cost of diabetes is $1.7 billion per 
year.15  
Uncontrolled or long-term diabetes can lead to microvascular complications. 
These include retinopathy, nephropathy, and neuropathy. The most prominent and 
common health complication associated with diabetes is diabetic neuropathy.  The 
American Diabetes Association (ADA) defines diabetic neuropathy as “the presence of 
symptoms and/or signs of peripheral nerve dysfunction in people with diabetes after 
exclusion of other causes”.16  Excess blood glucose can injure the capillaries that provide 
blood to nerves and interferes with the ability of nerves to transmit signals.17  There are 
four main types of diabetic neuropathies: peripheral neuropathy, autonomic neuropathy, 
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radiculoplexus neuropathy and mononeuropathy.17 The most common form is diabetic 
peripheral neuropathy.17 Symptoms of diabetic peripheral neuropathy include tingling, 
burning, pain, and loss of feeling that starts at the tips of the fingers and toes.16,17 
Symptoms tend to be worse at night and are often lessened by movement, walking or 
standing.16 However, problems balancing and walking are also commonly seen in 
individuals with diabetic peripheral neuropathy.16 Diabetic peripheral neuropathy may 
affect one or more nerves and over time can lead to the complete loss of feeling in entire 
limbs.16,17 The nerve damage that often results from diabetes puts the feet at an increased 
risk for foot complications.3 Minor cuts and blisters can become infected and amputations 
of extremities may be necessary in severe cases.3 More serious foot problems such as 
deformities and bone and joint pain can also result. Diabetic neuropathies affect as many 
as 50% of patients with diabetes to some degree.18 Of these individuals with diabetic 
peripheral neuropathy, there were 73,000 non-traumatic lower-limb amputations 
performed in 2010.5,19,20  
Because diabetic peripheral neuropathy has no known cure, treatment tends to 
focus on managing symptoms and slowing the progression of the disease.17 Wearing 
proper footwear, maintaining a healthy blood pressure, eating healthy, exercising, 
avoiding alcohol and smoking, as well as keeping the blood glucose within a target range 
can help to delay the progression of diabetic peripheral neuropathy.17 Diabetic peripheral 
neuropathy and its complications were estimated to cost between 4.6 and 13.7 billion 
dollars annually in the United States. In fact, up to 27% of the medical costs of diabetes 
in the United States is attributed to diabetic peripheral neuropathy.21   
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Due to the high potential for serious health problems caused by diabetic 
peripheral neuropathy, the ADA recommends that diabetic patients receive a 
comprehensive foot exam at least once per year.22 All patients should be screened for 
diabetic peripheral neuropathy beginning at diagnosis of T2DM and 5 years after the 
diagnosis of T1DM. Foot exams should check for various dermatologic conditions such 
as skin color, thickness, dryness, and cracking.19,22 The presence of ulcers, blisters and 
calluses should also be checked.22 In addition, a musculoskeletal assessment should be 
performed to look for deformities such as claw toes, prominent metatarsal heads, and 
charcot joints.19,22 Pedal pulses may also be checked in some instances. The presence of 
any of these conditions should be noted, and the patient should be referred to a physician 
if the results seem indicative of possible diabetic peripheral neuropathy.19 Patients with 
insensate feet, ulcers, and foot deformities should be examined at every physician visit 
rather than just once a year.10 
One other common and accurate way to test for diabetic peripheral neuropathy is 
through Semmes-Weinstein monofilaments (SWM).  These are typically made of fine 
nylon and designed “such that the amount of pressure on the plantar surface of the great 
toe is a function of the instrument, and not of the examiner”.16 SWM are single-fiber 
nylon threads, and each generates a buckling stress.16 Each monofilament “is marked 
with a number that represents the decimal log of 10 times the force in milligrams ranging 
from 1.65 (000.45 g) to 6.65 (447 g) of linear force.”16 To test for neuropathy, the 
monofilament is gently placed perpendicularly on the surface of the foot until the 
monofilament buckles.16 This action is repeated several times on various areas of the 
foot: the 1st, 3rd, and 5th metatarsal heads, and the plantar surface of the distal hallux.16 
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These four monofilament testing sites have been shown to identify 90% of patients with 
an insensate site.24 To test for complete loss of protective sensation, a 10g SWM should 
be used.16  Several studies have shown that use of the 10g SWM is highly predictive of 
future ulcerations, and its efficacy in screening for sensory loss has been confirmed in 
several studies.23 When conducting a monofilament test for neuropathy, the sensation of 
pressure using the 10g SWM should first be demonstrated for the patient on a proximal 
site such as the arm.23 The patient should close their eyes and respond with “yes” during 
the test whenever they feel the monofilament being applied.23 If the patient does not feel 
the monofilament after it buckles, then the test site is considered to be insensate.25 
Diabetes affects millions of Americans and is associated with many health 
complications that have various effects on the body. Diabetic peripheral neuropathy is 
one of the more common diabetes-related health complications and can have detrimental 
effects on an individual, so it is important that patients with diabetes receive foot exams 
regularly.  Performing a foot exam using a 10g SWM is an accurate and simple way to 
test for possible diabetic peripheral neuropathy.  Since many rural populations do not 
have easy access to healthcare, these populations have been shown to often have 
untreated health conditions.  However, data showing how diabetes in particular is 
monitored and managed in rural populations is limited. As a result, this study sought to 
test a rural population of people in a local community pharmacy using a 10g SWM to 
determine the prevalence of diabetic peripheral neuropathy as well as how often it goes 
undiagnosed by physicians in a rural population. The study also aims to analyze whether 
the treatment trends of diabetic peripheral neuropathy are correlated with those of 
diabetic retinopathy, another common sequelae of diabetes. By determining whether a 
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correlation exists, hopefully physicians can develop better treatment plans to improve 
patient care. The results of the study showing the prevalence of diabetic peripheral 
neuropathy will be shared with physicians to hopefully raise awareness for diabetic 
peripheral neuropathy and to help combat the adverse health risks associated with the 
condition.  
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MATERIALS AND METHODS 
 This study, “Evaluation of the Prevalence and Treatment Trends of Diabetic 
Peripheral Neuropathy among Patients with Diabetes in a Rural Population” was 
reviewed by the Institutional Review Board (IRB) at the University of Mississippi and 
approved. Patients of Prairieville Pharmacy, located in Prairieville, Louisiana were 
recruited as subjects. The pharmacist at Prairieville Pharmacy asked patients taking 
medications commonly used to treat diabetes if they would be willing to participate. 
Patients over the age of 18, with known diabetes mellitus, were eligible to participate.  
Each participant was given a randomized code to keep his or her anonymity. The 
participant was asked to complete a survey on Qualtrics asking various questions about 
how his or her diabetes is monitored and managed, as well as other questions to gauge the 
participant’s knowledge about his or her diabetes.  Then, the participant was asked to 
remove his or her shoes and socks on both feet. The investigator wore latex gloves, and 
used a new pair of latex gloves between each participant. The investigator performed a 
monofilament exam on the participant using a 10g Semmes-Weinstein monofilament 
(SWM). The 10g SWMs were purchased through Medical Monofilament. A new 10g 
SWM was used for each participant. The investigator first demonstrated for each 
participant how the 10g SWM would be used and how it felt by applying the 10g SWM 
to the participant’s forearm. Then, six sites on each foot were tested: the first, third, and 
fifth metatarsal heads; the plantar surface of the distal hallux and fifth phalanx; and the 
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dorsum pedis. (See Figure 2: Semmes-Weinstein Monofilament Test).  The investigator 
touched the 10g SWM to the same six sites on each foot in random order by applying just 
enough pressure to cause the 10g SWM to buckle. The six testing sites were chosen based 
on literature evaluations of the most accurate testing sites for detecting diabetic peripheral 
neuropathy. The participant was asked to close his or her eyes and to respond “yes” any 
time he or she felt the 10g SWM on his or her foot. If a participant did not respond “yes” 
when the monofilament was applied to a particular site, the test site was considered to be 
insensate. The number of “yes” responses was recorded on the participant’s Qualtrics 
survey. Next, the investigator checked for a bilateral pedal pulse in each participant. The 
bilateral pedal pulse was recorded as either “present” or “absent” for each participant. 
The pedal pulse must have been detected on both feet in order to be considered present. 
The presence or absence of the bilateral pedal pulse was recorded on the participant’s 
Qualtrics survey. At the end of each participant’s time, a total of twelve sites were 
evaluated with the 10g SWM. Each participant was offered a copy of the results from his 
or her monofilament exam to take to his or her physician. The investigator discarded the 
10g SWM and latex gloves into the proper trash receptacle.  
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FIGURE 2: Semmes-Weinstein Monofilament Test. From American Medical 
Association—2005 
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OBSERVATIONS 
 Throughout the study, various observations were noted. Roughly the same 
number of sensate test sites was observed on each foot, suggesting that the degree of 
feeling on each foot was approximately equal for most participants. The dorsum pedis 
was the site most commonly felt by participants. The first, third, and fifth metatarsal 
heads as well as the plantar surface of the distal hallux and fifth phalanx were distributed 
fairly equally in terms of how often participants responded “yes” to feeling the 10g 
SWM.  Participants with structural deformities in the bones of their feet had more 
insensate test sites than participants without structural deformities in their feet. Also, 
there was a general trend that participants with thick, callused skin on their feet had more 
insensate test sites compared to participants without calluses. In addition, participants 
who reported having physicians that provided regular foot exams tended to behave more 
confidently about how they would perform on the monofilament exam compared to 
participants whose physicians rarely performed foot examinations.  
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RESULTS 
Prevalence of Diabetic Peripheral Neuropathy in a Rural Population as Detected by 
10g Semmes-Weinstein Monofilament Exam 
 Using the software, SPSS, the data collected were transferred from the Qualtrics 
survey software to an SPSS document. To determine the prevalence of diabetic peripheral 
neuropathy in the sample of participants, the results of the 10g SWM were analyzed with 
SPSS. The number of “yes” responses to the monofilament exam was counted for each 
participant. Participants were considered to test negative for diabetic peripheral 
neuropathy if they had 10 or more “yes” responses. In other words, if the participant felt 
9 or less of the 12 testing sites on the foot, he or she was classified as having diabetic 
peripheral neuropathy. Descriptive statistics were used to determine the frequency of 
participants who felt 9 or less of the testing sites using the 10g SWM. It was found that 
15 of the 52 participants, or 28.8%, of the participants tested positive for diabetic 
peripheral neuropathy using the 10g SWM.  
 Next, the results of the survey question in which participants were asked 
to report whether or not they had ever been diagnosed with diabetic peripheral 
neuropathy were analyzed. Participants who answered that they were unsure if they had 
ever been diagnosed with diabetic peripheral neuropathy were classified as not having a 
diagnosis of diabetic peripheral neuropathy. The results showed that 11 of the 
participants, or 21.2%, reported a previous or current diagnosis of diabetic peripheral 
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neuropathy. (See Figure 3: Proportion of Participants Reporting a Diagnosis of Diabetic 
Peripheral Neuropathy)  
Then, a cross-tabulation was done to compare the survey responses with the 
results of the 10g SWM exam. The cross-tabulation identified 9 participants, or 17.3%, 
who tested positive for diabetic peripheral neuropathy from the 10g SWM exam that 
reported never being diagnosed with diabetic peripheral neuropathy in their survey 
responses. Additionally, 5 participants, or 9.62%, reported a previous or current diagnosis 
of diabetic peripheral neuropathy but tested negative for diabetic peripheral neuropathy 
based on their results of the 10g SWM exam. A McNemar test was used to compare the 
proportion of participants who reported a previous diagnosis of diabetic peripheral 
neuropathy to those who tested positive for diabetic peripheral neuropathy from the 10g 
SWM exam. A p-value of 0.424 was determined using a binomial distribution and a two-
tailed analysis, and thus concluded to be insignificant since p>0.05.  
 Therefore, it can be concluded that there was no statistically significant difference 
between the proportion of participants who reported having a previous diagnosis of 
diabetic peripheral neuropathy and the proportion of participants who tested positive for 
diabetic peripheral neuropathy based on their results from the 10g SWM exam. (See 
Figure 4: Comparison of Diagnosis of Diabetic Peripheral Neuropathy by Physician and 
Results of the 10g Semmes-Weinstein Monofilament Exam) 
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FIGURE 3: Proportion of Participants Reporting a Diagnosis of Diabetic Peripheral 
Neuropathy 
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FIGURE 4: Comparison of Diagnosis of Diabetic Peripheral Neuropathy by Physician 
and Results of the 10g Semmes-Weinstein Monofilament Exam 
 
 
 
 
	 18	
Relationship between Frequency of Foot and Eye Exams Among Patients with 
Diabetes in a Rural Population 
The ADA recommends that patients with diabetes receive a comprehensive foot 
and eye exam at least once per year, and more often if the patient is at an increased risk 
for, or has been diagnosed with diabetic peripheral neuropathy or diabetic retinopathy. To 
evaluate adherence to the ADA’s recommendations for patients with diabetes having an 
annual eye exam, data were collected through the Qualtrics survey software regarding the 
last time participants received an eye exam. Through SPSS, survey responses were 
grouped into having an eye exam “within the last year,” “over a year ago,” or 
“unknown.” Descriptive statistics were done that showed that 11.5% of participants had 
not had an eye exam in over a year, and 3.8%, or 2 participants, were not sure of how 
long it had been since their last eye exam.   
Next, to analyze adherence to the ADA’s recommendation that patients with 
diabetes have an annual foot exam, data were collected through the Qualtrics survey 
software regarding whether or not the physician managing the participant’s diabetes 
performs regular examinations of the participant’s feet. Participants were first asked 
whether or not their physician performs regular examinations of their feet to check for 
bone deformities, slow healing wounds, and loss of feeling. Then, participants were asked 
how frequently their doctor performed such foot exams. Survey responses were 
categorized through SPSS into either “yes, participant has foot exam at least once 
annually” or “no, participant does not receive annual foot exam.” The results showed that 
71.2% of participants receive an annual foot exam, and 28.8% of participants do not 
receive an annual foot exam.   
	 19	
Then, to determine whether there was a relationship between how frequently 
participants received foot and eye exams, a cross-tabulation was performed using the 
categories of survey responses mentioned above. An odds ratio was calculated to be 3.0, 
meaning that participants whose physicians performed regular foot exams were 3.0 times 
as likely to have an annual eye exam compared to participants whose physicians did not 
perform regular foot exams. By running a Pearson chi-square test, a two-sided p-value of 
0.20 was obtained, and thus insignificant because the p-value was greater than 0.05.  
It can be concluded that there was no statistically significant relationship between 
the frequency of having foot and eye exams. However, because there was a general trend 
that participants who receive annual foot exams are more likely to have an annual eye 
exam, the results may be significant from a clinical perspective. (See Figure 5: 
Comparison of the Proportion of Participants who had an Eye Exam within the Last Year 
Given that their Physician Performs Regular Foot Examinations)  
 
Effect of Attending Diabetes Self-Management Class on Adherence to ADA’s 
Recommendations for Foot and Eye Exams 
 To determine whether or not attending diabetes self-management class affects 
adherence to the ADA’s guidelines for foot and eye exams, the proportion of participants 
who have attended diabetes self-management class was first determined. A survey 
question was developed through Qualtrics in which participants were asked whether they 
had ever attended a diabetes self-management class. The results were analyzed using 
SPSS to show that 38.5% of participants had never attended a diabetes self-management 
class, while 61.5% of participants had attended a diabetes self-management class.  
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FIGURE 5: Comparison of the Proportion of Participants who had an Eye Exam within  
the Last Year Given that their Physician Performs Regular Foot Examinations 
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Next, a cross-tabulation was performed to determine whether attending a diabetes 
self-management class impacted adherence to the ADA’s eye exam guidelines. Two 
participants were excluded from this analysis because they were unsure of the timing of 
their last eye exam. Out of the 31 participants included who had attended a self-
management class, 90.3% had an eye exam within the last year. Out of the 19 participants 
who had not attended a self-management class, 84.2% had an eye exam within the last 
year. A Fisher’s Exact Test was performed, and a two-sided p-value of 0.661 was 
obtained. Since p>0.05, the results were not statistically significant.  
 Then, another cross-tabulation was done to evaluate whether attending a diabetes 
self-management class impacted adherence to the ADA’s foot exam guidelines. Out of 
the 32 participants who had attended a self-management class, 78.1% reported having 
regular foot exams performed by their physician. Of the 20 participants who had never 
attended a self-management class, 60.0% reported having regular foot exams performed 
by their physician. A Fisher’s Exact Test was done, and a p-value of 0.213 was obtained 
using a two-tailed analysis. Therefore, the results were not statistically significant since p 
was greater than 0.05. Although the effect of attending a diabetes self-management class 
was not statistically significant, there is a general trend that participants who attended a 
self-management class were more adherent to the ADA’s recommendations for foot and 
eye exams. 
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DISCUSSION 
 
Regularly testing for and monitoring the common health complications of 
diabetes mellitus plays a vital role in patient health care. Nearly half of all patients with 
diabetes are affected by diabetic neuropathies, a condition that can be deadly and 
debilitating without proper management. Ensuring that all patients with diabetes receive 
the proper care for such health complications as outlined by the American Diabetes 
Association is necessary and important.  This is especially true in populations that have 
limited access to or education about diabetes management, such as in a rural setting. This 
study aimed to evaluate the prevalence of two of the common health complications of 
diabetes and to determine how well these conditions were being tested for and monitored 
in a rural population. By asking participants to provide information about their diabetes 
management and then checking their feet for neuropathy with the monofilament test, the 
investigator was able to compare their current understanding of their health with the 
results from a reliable test for diabetic peripheral neuropathy. Almost one-third of all 
participants showed signs of diabetic peripheral neuropathy through the monofilament 
test. With such a high percentage of participants affected, these results confirm the 
importance of testing for diabetic neuropathies. More importantly, over half of all 
participants identified by the 10g SWM to have diabetic peripheral neuropathy were 
undiagnosed by the physician managing their diabetes. Although not statistically 
significant, these results are of clinical significance since they provide evidence that a 
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considerable number of patients with diabetes in this rural population are not receiving 
proper care for these serious health conditions. With a larger sample size, the results 
could become statistically significant as well.   
This study also analyzed whether there is a relationship between how frequently 
patients with diabetes have foot and eye exams. Knowing if there is a relationship can be 
helpful so that physicians may understand whether improving one area of patient care 
may have similar effects on other areas of patient care as well.  The investigator first 
identified that over a quarter of all participants did not receive annual foot exams, and 
roughly 15% did not have annual eye exams. These results indicate that while the 
majority of patients with diabetes in this particular rural population were adherent to the 
ADA’s recommendations for foot and eye exams, improvements are still necessary. More 
specific data related to diabetes management and prevention of disease complications in 
underserved areas is warranted; however, this study suggests that rural populations need 
greater attention and targeted educational programs to enhance the level of care.  
The results also showed that participants who receive annual foot exams were 
three times as likely to have annual eye exams. Although these results were not 
statistically significant due to a limited sample size, the results hold some degree of 
clinical significance. Understanding the relationship between the management of health 
complications of diabetes is important. The results suggest that improvements in one area 
of patient care may positively affect other areas of patient care. This is especially helpful 
in rural populations where access to health care is often more limited. Encouraging 
adherence to one aspect of the ADA’s guidelines for managing the complications of 
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diabetes can increase adherence to other aspects as well, leading to an overall 
improvement in patient health outcomes.  
Another aspect of diabetes care analyzed by this study was whether attending a 
diabetes self-management class improved patient adherence to receiving annual foot and 
eye exams. The results showed that only about sixty percent of participants had ever 
attended a self-management class. Since such a low percentage of participants have 
received proper education about managing their diabetes, improvements in patient 
education in this rural populations are needed. Education about proper management of 
diabetes is crucial so that patients may understand what signs and symptoms to watch for 
and how to prevent some of the debilitating sequelae of diabetes.  
Although the results were not statistically significant, it was found that there was 
a roughly six percent increase in the number of participants who had annual eye exams in 
the participants who had attended a diabetes self-management class compared to 
participants who had not attended a self-management class. Additionally, there was about 
a twenty percent increase in the number of participants who had annual foot exams in 
participants who had attended a self-management class compared to those who had not 
attended a self-management class. If a larger sample size had been used, these results 
could have been statistically significant. Regardless, these results certainly appear to 
possess significance clinically since there was an observed general trend that participants 
who have proper education about how to manage their diabetes have improved adherence 
to the ADA’s guidelines for foot and eye exams. Understanding that education improves 
patient self-management provides support that educating patients and providing them 
with educational opportunities is valuable and can lead to improved health outcomes.  
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Proper management of diabetes includes more than just maintaining blood 
glucose levels. Patients with diabetes should be aware of the effects of diabetes on 
several other body systems. Patients and physicians should work together to ensure that 
patients are properly educated about the importance of having annual foot and eye exams. 
Furthermore, physicians should understand the importance of regularly examining their 
patients for potential complications of diabetes. Patients in rural populations are often at 
an increased risk for health complications due to limited access to health care facilities 
and fewer educational opportunities. Although greater patient care may be needed across 
all populations, it can be concluded from this study that patients in rural populations may 
be in need of additional improvements in patient care. In the rural population included in 
this study, there were a considerable number of patients who did not have regular foot 
and eye exams and who had undiagnosed diabetic peripheral neuropathy. The results 
verify the need for continued work toward greater diabetes care and provide insight into 
the value of diabetes self-management education.  
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Appendix A: Patient Survey 
We will be looking at patients with diabetes. We want to see how many people have lost 
some feeling in their feet and how often they have their feet looked at by a doctor. To 
find this out, we want you to answer some questions that deal with your medical history 
in regards to diabetes, diabetes complications, and foot-care. Your name will not be 
recorded for any reason. The only information recorded will be whether you are male or 
female, your age, and your ethnicity. You may skip any questions that you do not feel 
comfortable answering. If you start the study and decide that you do not want to finish, 
you may stop at any time. Whether or not you choose to participate or to withdraw will 
not affect you in any way. Thank you in advance for your time! 
 1. Have	you	ever	been	diagnosed	with	diabetes?	a. Yes	b. No	
 2. If	yes,	what	type	of	diabetes	were	you	diagnosed	with?	a. Type	1	b. Type	2	c. Gestational	d. I	don’t	know		3. How	many	years	have	you	been	diagnosed	with	diabetes?	________________________		4. Does	your	physician	perform	regular	examinations	of	your	feet	to	check	for	bone	deformities	or	slow-healing	wounds?	a. Yes	b. No		5. Have	you	ever	had	a	monofilament	exam?	a. Yes	b. No	c. Not	sure		6. If	yes,	about	how	many	times	have	you	had	a	monofilament	exam?	(skip	to	question	7	if	you	answered	“no”	to	question	5)	a. One	time	b. A	few	times	c. Once	a	year	
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d. More	than	once	a	year		7. Have	you	ever	been	diagnosed	with	peripheral	neuropathy?	a. Yes	b. No	c. Not	sure	8. If	so,	at	what	age	were	you	first	diagnosed	with	peripheral	neuropathy?	_________________________		9. Do	you	check	your	feet	regularly	for	blisters,	ulcers,	calluses,	and	ingrown	toenails?	a. Yes	b. No		10. How	long	does	it	typically	take	for	your	foot	wounds	to	heal?	a. 2-4	days	b. About	1	week	c. About	2	weeks	d. Longer	than	2	weeks		11. When	was	the	last	time	you	had	an	eye	exam?	__________________________________		12. Has	your	doctor	ever	made	you	pee	in	a	cup?	a. Yes	b. No		13. Do	you	have	microalbuminuria	(protein	in	the	urine)?	a. Yes	b. No		14. Do	you	currently	take	medication	for	diabetes	management?	a. Yes	b. No		15. If	yes,	what	type	of	diabetes	medications	do	you	take?	Circle	all	that	apply.	a. Oral	(pill)	b. Injection	c. Insulin		16. Do	you	take	insulin?	a. Yes	b. No		17. Do	you	take	your	medications	as	instructed?	a. Yes		b. No	
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	18. During	the	past	24	hours,	how	many	different	kinds	of	medication	have	you	taken	(including	diabetic	and	non-diabetic	medications)?	______________________________________		19. If	you	have	taken	medication	in	the	last	24	hours,	how	many	of	the	medications	you	have	taken	have	been	prescribed	by	your	physician	(including	diabetic	and	non-diabetic	medications)?	_____________________________________		20. Have	you	ever	attended	diabetes	self-management	class?	a. Yes	b. No		21. What	kind	of	physician	do	you	see	for	your	diabetes?	a. Primary	care	physician/family	doctor	b. Endocrinologist	c. Other			22. Do	you	know	your	last	A1C	(hemoglobin	A1C)	a. Yes	b. No		23. If	so,	what	was	your	last	A1C	(hemoglobin	A1C)?	______________________		24. Do	you	smoke?	a. Yes	b. No		25. If	so,	about	how	many	cigarettes	do	you	smoke	per	day?	_______________________		26. How	many	years	have	you	smoked?	___________________________		27. Age	category:	a. 18-25	b. 26-30	c. 31-35	d. 36-40	e. 41-45	f. 46-50	g. 51-55	h. 56-60	i. 61-65	j. 66-70	k. 71-75	l. 76-80	
	 35	
m. 81+		28. Gender	a. Male	b. Female		29. Ethnicity:	a. Caucasian	b. African	American/Black	c. Hispanic/Latino	d. Pacific	Islander	e. Native	American/Alaskan	f. Asian	g. Other	
 
Thank you for your participation!  
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Appendix B: Monofilament Exam Form 
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Appendix C: Patient Consent Letter 
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